Hereditary hypophosphatemia in adults;Hypophosphatémies génétiquement dé terminées chez l'adulte

Presse Medicale

Volumn 34, Issue 22 I, 2005, Pages 1720-1726

  Velayoudom Cephise F L ^a   Vantyghem, M C ^a   Wemeau J L ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DIPYRIDAMOLE; ETIDRONIC ACID; FIBROBLAST GROWTH FACTOR 23; OXYGENASE; PHOSPHATE TRANSPORTER; PROTEIN; VITAMIN D;

CHROMOSOME XP; DIFFERENTIAL DIAGNOSIS; GENE LOCATION; GENETIC DISORDER; HUMAN; OSTEOMALACIA; PROTEIN EXPRESSION; REVIEW; RICKETS; VITAMIN D DEFICIENCY; VITAMIN D RESISTANT RICKETS; X CHROMOSOME RECESSIVE DISORDER;

EID: 33344474617     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84260-5     Document Type: Short Survey

References (49)

1. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977; 137: 203-20.
2. Laroche M. Phosphate, the renal tubule, and the musculoskeletal system. Joint Bone Spine 2001; 68: 211-15.
3. Lotz M, Zisman E, Bartter FC. There is evidence for a phosphorus depletion syndrome in man. N Engl J Med 1968; 278: 409-14.
4. Lefebvre J, Leclerc L, Vantyghem MC, Lepeut M. Les hypophosphoré mies: stratégies diagnostique et thérapeutique. Rev Franç Endocrinol 1989; 30: 457-66.
5. Koeger AC, Prier A, Vinceneux P, Camus JP. Les ostéomalacies tumorales hypophosphorémiques. Presse Med 1985; 14: 1747-51.
6. Albright F, Butler AM, Bloomberg E. Rickets resistant to Vitamin D therapy. Am J Dis Chil 1937; 54: 529-47.
7. Thakker RU, O'Riordan JL. Inherited form of rickets and osteomalacia. Baillieres Clinical Endocrinol Metab 1988; 2: 157-91.
8. Brame LA, White KE, Econs MJ. Renal phosphate wasting disorders: clinical features and pathogenesis. Semin Nephrol 2004; 24: 39-47.
9. Jan de Beur SM, Levine MA. Molecular Pathogenesis of hypophosphatemic rickets. J Clin Endocrinol Metabol 2002; 87: 2467-73.
10. Tenenhouse HS, Martel J. Renal adaptation to phosphate deprivation: lessons from the X-linked Hyp mouse. Pediatr Nephrol 1993; 7: 312-18.
11. Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995; 11: 130-6.
12. Scheinman SJ, Pook MA, Wooding C, Pang JT, Frymoyer PA, Thakker RV. Mapping the gene causing X-linked recessive nephrolithiasis to Xp11.22 by linkage studies. J Clin Invest 1993; 91: 2351-7.
13. Dixon P, Christie PT, Wooding C, Trump D, Grieff M, Holm I et al. Mutational analysis of PHEX gene in X-linked hypophosphatemia. J Clin Endocrinol Metab 1998; 83: 3615-23.
14. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goddyer CG et al. Pex/PEX tissue distribution and evidence for a deletion in the 3′region of the Pex gene in X-Linked hypophosphatemic mice. J Clin Invest 1997; 99: 1200-9.
15. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metabol 2003; 285: E1-E9.
16. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001; 284: 977-81.
17. Guo R, Liu S, Spurney RF, Quarles LD. Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 2001; 281: E837-47.
18. Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT et al. Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metabol 2001; 86: 3889-99.
19. Makitie O, Kooh SW, Sochett E. Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol 2003; 58: 163-8.
20. Verge CE, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991; 325: 1843-8.
21. Seikaly MG, Quigley R, Baum M. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia. Pediatr Nephrol 2000 15: 57-9.
22. Prie D, Blanchet FB, Essig M, Jourdain JP, Friedlander G. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol 1998; 9: 1264-9.
23. Econs MJ, McEnery PT, Lennon F, Speer M. Autosomal dominant hypophosphatemic rickets is linked to chromosome 12p13. J Clin Invest 1997; 100: 2653-7.
24. Silve C, Beck L. Is FGF 23 the long sought after phosphaturic factor phosphatonin? Nephrol Dial Transplant 2002; 17: 958-61.
25. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-60.
26. Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, Gabizon D, Liberman UA. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985; 312: 611-17.
27. Sorribas V, Markovich D, Hayes G, Stange G, Forgo J, Biber J et al. Cloning of a Na/Pi cotransporter from opossum kidney cells. J Biol Chem 1994; 269: 6615-21.
28. Hoag HM, Martel J, Gauthier C, Tenenhouse HS. Effects of Npt2 gene ablation and low-phosphate diet on renal Na+/Phosphate cotransport and cotransport gene expression. J Clin Inv 1999; 104: 679-86.
29. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80: 1373-409.
30. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciurie, and skeletal abnormalities. Proc Natl Acad Sci USA 1998; 95: 5372-7.
31. Van den Heuvel L, Op de Koul K, Knots E, Knoers N, Monnens L. Autosomal recessive hypophosphataemic rickets with hypercalciuria is not caused by mutations in the type II renal sodium/phosphate cotransporter gene. Nephrol Dial Transplant 2001; 16: 48-51.
32. Jones A, Tzenova J, Frappier D, Crumley M, Roslin N, Kos C et al. Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. J Am Soc Nephrol 2001; 12: 507-14.
33. Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002; 347: 983-91.
34. Ryan EA, Reiss E. Oncogenous osteomalacia. Am J Med 1984; 77: 501-12.
35. Seufert J, Ebert K, Müller J, Eulert J, Hendrich C, Werner E et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001; 345: 1883-8.
36. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 2000; 20: 333-8.
37. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR et al. Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994; 330: 1645-9.
38. Carpenter TO. Oncogenic octeomalacia a complex dance of factors. N Engl J Med 2003; 348: 1705-8.
39. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000; 67: 54-68.
40. Yoshiko Y, Aubin JE, Maeda N. Stanniocalcin 1 (STC1) protein and mRNA are developmentally regulated during embryonic mouse osteogenesis: the potential of STC1 as an autocrine/paracrine factor for osteoblast development and bone formation. J Histochem 2002; 50: 483-92.
41. Yeung SJ, McCutcheon IE, Schultz P, Gagel RF. Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia. J Clin Endocrinol Metab 2000; 85: 549-55.
42. Scheinman SJ, Guay-Woodford LM, Thakker RV, Warnock DG. Genetic disorders of renal electrolyte transport. N Engl J Med 1999; 340: 1177-87.
43. Lloyd SE, Günther W, Pearce SH, Thomson A, Bianchi ML, Bosio M et al. Characterisation of renal chloride channel, CLCN5, mutations in hypercalciuric nephrolithiasis (kidney stones) disorders. Hum Mol Genet 1997; 6: 1233-9.
44. Thakker RV. Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis. Kidney Int 2000; 57: 787-93.
45. Saint-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-def iciency rickets (PPDR) disease locus. J Bone Miner Res 1997; 12: 1552-9.
46. Saint-Arnaud R, Dardenne O, Glorieux FH. Etiologie moléculaire des rachitismes vitaminodépendants héréditaires. MIS 2001; 17: 1289-96.
47. Labuda M, Morgan K, Glorieux FH. Mapping autosomal recessive vitamin D dependancy type I to chromosome 12q14 by linkage analysis. Am J Hum Genet 1990; 47: 28-36.
48. Kitanaka S, Murayama A, Sakaki T, Inouve K, Seino Y, Fukumoto S et al. No enzyme activity of 25-hydroxyvitamin D3 1alpha-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J Clin Endocrinol Metab 1999; 84: 4111-17.
49. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1, 25-dihydroxyvitamin D-resistant rickets. Endocrine Reviews 1999; 20: 156-88.